Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251095 · ClinicalTrials.gov registry record · Phase 3
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
A Phase 3 study, sponsored by Achieve Life Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 821
- Enrollment target
NCT00251095: Clinical Trial Phase 3 study, sponsored by Achieve Life Sciences.
NCT00251095 is a Phase 3 study that was terminated before completion, run by Achieve Life Sciences. The registered enrollment target is 821 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00251095, a Phase 3 study, was terminated before completion, sponsored by Achieve Life Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 821 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCOSOL Paclitaxel given every week is non-inferior to that observed with Taxol given every week.
Interventions
- DRUG Taxol
- DRUG TOCOSOL Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 821 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Why NCT00251095 stopped before completion
NCT00251095 is an interventional study that assigns participants to a tested intervention. The registered 821 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Taxol is the first listed.
NCT00251095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00251095 about?
NCT00251095 is a clinical study titled "Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer". The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection) administered every week to patients with metastatic breast cancer. The study hypothesis is that the objective response rate with TOCO...
What is the current status of trial NCT00251095?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 821 participants. The study started on 2005-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00251095?
The interventions under investigation include: Taxol (DRUG), TOCOSOL Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00251095?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00251095's enrollment target sits among peer trials
821 404th of 2000 higher than 1,597 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
- NCT06091254 · 822 participants · Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- NCT07357389 · 822 participants · NA
Virtual Reality for ICU Delirium Prevention
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia